{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+hematopoietic+stem+cell+transplantation&page=78", "query": { "intervention": "Autologous hematopoietic stem cell transplantation", "page": 78 }, "page_size": 10 }, "pagination": { "page": 78, "page_size": 10, "total_count": 2704, "total_pages": 271, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+hematopoietic+stem+cell+transplantation&page=79&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+hematopoietic+stem+cell+transplantation&page=77&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T00:00:55.115Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00622232", "title": "A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VRX496-transduced autologous CD4 T cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "VIRxSYS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-12", "completion_date": "2023-06", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 2, "location_summary": "Norwalk, Connecticut • New York, New York", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622232" }, { "nct_id": "NCT02234193", "title": "Reducing Side-effects of Autologous Skin Tissue Harvesting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Scar" ], "interventions": [ { "name": "Micro biopsy", "type": "DEVICE" }, { "name": "Lidocaine with epinephrine", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 8, "start_date": "2016-06-01", "completion_date": "2019-03-01", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234193" }, { "nct_id": "NCT00002649", "title": "Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "16 Years to 60 Years" }, "enrollment_count": 206, "start_date": "1995-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002649" }, { "nct_id": "NCT06201416", "title": "Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SBT777101", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sonoma Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2024-03-06", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06201416" }, { "nct_id": "NCT01061840", "title": "Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewings Sarcoma", "Non Small Cell Lung Cancer", "Liver Cancer" ], "interventions": [ { "name": "Vigil™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2009-12", "completion_date": "2019-01", "has_results": false, "last_update_posted_date": "2022-03-15", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 4, "location_summary": "West Palm Beach, Florida • Lebanon, New Hampshire • Dallas, Texas + 1 more", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Dallas", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061840" }, { "nct_id": "NCT01087697", "title": "Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Neo-Urinary Conduit", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Tengion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 8, "start_date": "2010-03", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-10", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 6, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087697" }, { "nct_id": "NCT04099797", "title": "C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "High Grade Glioma", "Embryonal Tumor", "Ependymal Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells (IV and ICV infusion)", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "12 Months to 25 Years" }, "enrollment_count": 56, "start_date": "2020-02-03", "completion_date": "2041-02", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099797" }, { "nct_id": "NCT02010606", "title": "Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioma", "Astrocytoma", "Brain Tumor" ], "interventions": [ { "name": "Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy", "type": "BIOLOGICAL" }, { "name": "Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2014-01-08", "completion_date": "2021-07-10", "has_results": false, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010606" }, { "nct_id": "NCT00272649", "title": "Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "AGS-003", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Argos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2006-01", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-03-14", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00272649" }, { "nct_id": "NCT04876248", "title": "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Belantamab Mafodotin", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-08-19", "completion_date": "2027-07-29", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-04T00:00:55.115Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04876248" } ] }